Some randomised controlled trials (RCTs) of dual antiplatelet therapy for patients who had a ischaemic stroke
| RCT | CARESS | CLAIR | FASTER | CHANCE | POINT | PRINCE | THALES | CHANCE-2 | INSPIRES |
| Population | |||||||||
| Age, years | ＞18 | ≥18 | ≥40 | ≥40 | ≥18 | 40–80 | ≥40 | ≥40 | 35–80 |
| NIHSS (stroke） | – | <8 | ≤3 | ≤3 | ≤3 | ≤3 | ≤5 | ≤3 | ≤5 |
| ABCD2 (TIA) | – | – | – | ≥4 | ≥4 | ≥4 | ≥6 | ≥4 | ≥4 |
| Stenosis | ≥50%(symptomatic carotid) | ≥50% (symptomatic internal carotid or middle cerebral) | – | – | – | ≥50%(symptomatic cervical or intracranial) | ≥50%(symptomatic intra-/extracranial) | – | ≥50%(symptomatic intracranial/extracranial) or multiple infarctions of atherosclerotic origin |
| Start | ≤3 months | ≤7 days | ≤24 hours | ≤24 hours | ≤12 hours | ≤24 hours | ≤24 hours | ≤24 hours | ≤72 hours |
| Intervention | ASA+CLOP | ASA+CLOP | ASA+CLOP (Simvastatin) | ASA+CLOP | ASA+CLOP | ASA+TICA | ASA+TICA | ASA+TICA | ASA+CLOP (atorvastatin) |
| Control | ASA+placebo | ASA | ASA+placebo | ASA+placebo | ASA+placebo | ASA+CLOP | ASA+placebo | ASA+CLOP | ASA+placebo |
| Dose | CLOP 75 mg/day (first dose 600 mg) for first 7 days ASA 75 mg/day | CLOP 75 mg/day (first dose 600 mg) ASA 75–160 mg/day | CLOP 75 mg/day (first dose 300 mg) ASA 81 mg/day (first dose 162 mg) | CLOP 75 mg/day (first dose 300 mg) ASA 75 mg/day for first 21 days (first dose 75–300 mg) | CLOP 75 mg/day (first dose 600 mg) ASA 50–325 mg/day | TICA 90 mg two times per day (first dose 180 mg) CLOP 75 mg/day (first dose 300 mg) ASA 100 mg/day for first 21 days | TICA 90 mg two times per day (first dose 180 mg) ASA 75–100 mg/day (first dose 300–325 mg) | TICA 90 mg two times per day (first dose 180 mg) CLOP 75 mg/day (first dose 300 mg) ASA 75 mg/day for first 21 days (first dose 75–300 mg) | CLOP 75 mg/day (first dose 300 mg) ASA 100 mg/day for first 21 days (first dose 100–300 mg) |
| Primary outcome | Proportion of MES positive patients in 1 hour on day 7 | Proportion of patients detected MES on day 2 | Stroke at 90 days | Stroke at 90 days | Stroke, MI, vascular death at 90 days | proportion of patients with high platelet reactivity at 90 days | Stroke/death at 30 days | Stroke at 90 days | Stroke at 90 days |
| N | 107 | 100 | 392 | 5170 | 4881 | 675 | 11 016 | 6396 | 6100 |
ASA, aspirin; CLOP, clopidogrel; MES, microembolic signals; MI, myocardial Infarction; NIHSS, National Institutes of Health Stroke Scale; TIA, transient ischaemic attack; TICA, ticagrelor.